Real-World Outcomes With Axicabtagene Ciloleucel Therapy for Large B-Cell Lymphoma
Posted: 08/12/2022 | By: Chase Doyle

In clinical trials of CAR T-cell therapies and real-world studies published to date, there is a paucity of data on outcomes by race and ethnicity. In a study presented by Locke et al at the 2022 ASCO Annual Meeting, a research team examined outcomes by race and ethnicity among patients with large B-cell lymphoma who received the CAR T-cell therapy axicabtagene ciloleucel in the real-world setting.

Question 1 of 5

Compared to White patients, Black patients receiving axicabtagene ciloleucel in the real-world setting were more likely to be/have which of the following?

Choose 1